110 related articles for article (PubMed ID: 10595360)
1. Intracellular distribution of digoxigenin-labeled phosphorothioate oligonucleotides.
Tarrasón G; Bellido D; Eritja R; Vilaró S; Piulats J
Methods Enzymol; 2000; 313():257-68. PubMed ID: 10595360
[No Abstract] [Full Text] [Related]
2. Digoxigenin-labeled phosphorothioate oligonucleotides: a new tool for the study of cellular uptake.
Tarrasón G; Bellido D; Eritja R; Vilaró S; Piulats J
Antisense Res Dev; 1995; 5(3):193-201. PubMed ID: 8785475
[TBL] [Abstract][Full Text] [Related]
3. Polyethyleneimine-mediated transfection to improve antisense activity of 3'-capped phosphodiester oligonucleotides.
Dheur S; Saison-Behmoaras TE
Methods Enzymol; 2000; 313():56-73. PubMed ID: 10595349
[No Abstract] [Full Text] [Related]
4. Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus.
Jensen KD; Kopecková P; Kopecek J
Bioconjug Chem; 2002; 13(5):975-84. PubMed ID: 12236779
[TBL] [Abstract][Full Text] [Related]
5. Determination of cellular internalization of fluoresceinated oligonucleotides.
Benimetskaya L; Tonkinson J; Stein CA
Methods Enzymol; 2000; 313():287-97. PubMed ID: 10595362
[No Abstract] [Full Text] [Related]
6. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic properties of oligonucleotides in brain.
Sommer W; Hebb MO; Heilig M
Methods Enzymol; 2000; 314():261-75. PubMed ID: 10565019
[No Abstract] [Full Text] [Related]
8. Intrabody tissue-specific delivery of antisense conjugates in animals: ligand-linker-antisense oligomer conjugates.
Duff RJ; Deamond SF; Roby C; Zhou Y; Ts'o PO
Methods Enzymol; 2000; 313():297-321. PubMed ID: 10595363
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
Geary RS; Yu RZ; Levin AA
Curr Opin Investig Drugs; 2001 Apr; 2(4):562-73. PubMed ID: 11566019
[TBL] [Abstract][Full Text] [Related]
10. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation.
Bijsterbosch MK; Rump ET; De Vrueh RL; Dorland R; van Veghel R; Tivel KL; Biessen EA; van Berkel TJ; Manoharan M
Nucleic Acids Res; 2000 Jul; 28(14):2717-25. PubMed ID: 10908328
[TBL] [Abstract][Full Text] [Related]
11. Antisense phosphorothioate oligodeoxyribonucleotide targeted against ICAM-1: synthetic and biological characterization of a process-related impurity formed during oligonucleotide synthesis.
Ravikumar VT; Capaldi DC; Lima WF; Lesnik E; Turney B; Cole DL
Bioorg Med Chem; 2003 Oct; 11(21):4673-9. PubMed ID: 14527564
[TBL] [Abstract][Full Text] [Related]
12. ISIS 2302. INXC ICAM1, Oligo-TCS.
Drugs R D; 1999 Jan; 1(1):85-6. PubMed ID: 10565996
[No Abstract] [Full Text] [Related]
13. ISIS 2302. Oligo-TCS.
Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
[No Abstract] [Full Text] [Related]
14. The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5'-nucleotidase.
Koziolkiewicz M; Gendaszewska E; Maszewska M; Stein CA; Stec WJ
Blood; 2001 Aug; 98(4):995-1002. PubMed ID: 11493444
[TBL] [Abstract][Full Text] [Related]
15. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression.
Uhlmann E; Peyman A; Ryte A; Schmidt A; Buddecke E
Methods Enzymol; 2000; 313():268-84. PubMed ID: 10595361
[No Abstract] [Full Text] [Related]
16. Biologically active antisense phosphorothioate oligodeoxyribonucleotides: synthesis, characterization, and studies of 3'-terminal phosphorothioate monoester analogues.
Ravikumar VT; Lima WF; Van Sooy K; Turney B
Nucleosides Nucleotides Nucleic Acids; 2004; 23(1-2):149-60. PubMed ID: 15043143
[TBL] [Abstract][Full Text] [Related]
17. Cationic liposomes/lipids for oligonucleotide delivery: application to the inhibition of tumorigenicity of Kaposi's sarcoma by vascular endothelial growth factor antisense oligodeoxynucleotides.
Lavigne C; Lunardi-Iskandar Y; Lebleu B; Thierry AR
Methods Enzymol; 2004; 387():189-210. PubMed ID: 15172165
[No Abstract] [Full Text] [Related]
18. Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment.
Mata JE; Bishop MR; Tarantolo SR; Angel CR; Swanson SA; Iversen PL
J Toxicol Clin Toxicol; 2000; 38(4):383-7. PubMed ID: 10930054
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and properties of novel antisense oligonucleotides bearing an anthraquinone moiety at an internucleotide linkage.
Miyashita T; Mori K; Shinozuka K
Nucleic Acids Symp Ser; 1999; (42):163-4. PubMed ID: 10780430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
